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In conclusion, TEC atheractomy led to enhanced clinical safety in percu-
taneous revascularization during acute ischemicstates, while augmenting-6-
month outcome. Ita routine use during acute ischemic syndrome revaecular-
izatlon may now be considered for the technloally suitable vessel. Six month
follow up to be presented.
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FrequentAfterPrimeryPTCAforAcute
MyocardlalInfarction
D. Czitrom, E. Brochet, D. Karila-Cohen, P.Seknadji, J.-M. Juliard,
P.G.Steg, P.Assayag. Service de Cardiologie, Hopital Bichat, Paris, France
No-reflow, defined as incomplete recovery of myocardial perfusion after re-
establishment of patency of the infarct-related artery during acute myooardial
infarction (Ml), has been linked to worse prognosis, including heart failure
and left ventricular remodeling.
We prospectively studied no reflow by myocardial contrast echocerdio-
grephy (MCE) in 14 Pts with acute Ml (10 anterior and 4 inferior), treated by
primary PTCAwithin 6 hours (average time to TIMI 3 patency: 212 * 12 rein)
of Ml onset. MCE was performed by injection of sonicated ioxaglate in both
Infarc+ and non-infarct-related aiteries during corona~ angiography acutely.
Coronary angiography and simultaneous MCE were repeated 9 + 1 days
later. Myocerdial perfusion was graded semi-quantitatively by 2 independent
observers using a score of O, 0.5 and 1 for each ASE echocardiographic
segment from the myocardial area at risk (defined as hype- or akinetic seg-
ments; n = 95 segments). Echographic wall motion was graded on a score
from 1 (normokinesia) to 3 (akinesia).
After PTCA-induced TIMI 3 patency, MCE score was Oin 20%, 0.5 in 27%
and 1 In 53% of segments, respectively. At restudy, this score was Oin 10%,
0.5 in 14% and 1 in 76% of segments, respectively. Therefore, perfusion
was abnormal in 47% of segments acutely and in only 24% at predischarge
(p = 0.006). The average perfusion score per segment was O.W + 0.04
acutely and increased to 0.82 + 0.03 at restudy (p= 0.001). This increase in
“perfusion score was associated with a decrease in the average wall motion
grade: 2.8 * 0.04 acutely and 2.5+ 0.08 at day 9 (p < 0.01).
This important recovev of MCE-assessad myocardial perfusion within
daya (despite substantial acute no-reflow) suggests that primaty PTCA-
induced reperfusion results in effective protection of the myccardial mi-
crovasculature and may explain the early functional recovery,assessed by
echocardiography.
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consecutive patients with AMI for direct
PTCA between 1991 and 1995. Twenty (Group 1) received intracoronary
adenoeine (4 mg over 4 minutea) and 20 intracoronaty saline (Group ii).
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+ O I 2.7 + 0.6 in group 11,p = 0.043), in
the incidence of Q wave Ml (50% in group i vs 80% in group H,p = 0.0467)
end of clinically assesed LV failure (O% in groupI vs 20% in group H,p =
0.035). Peak CPK value was higher in saline patients (1994 + 1782 UI in
group I va 2803 + 1857 UI in group H,p = NS).
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Hospital, Osaka, Japan, 1Kawachi General Hospital, Higashi-Osaka, Japan
Salutary effect of nlcorandll, a K+-ATP channel opener, on restoration of
myocardial blood flow and functional improvement after ooronary revascular-
ization was investigated. Twenty patients with first anterior acute myocardial
infarction (AMI) who underwent coronary recanalization within 6 hours of the
onset were divided Into 2 groups: 10’patients who raoeived an adjunotive
intracomnary dose of 2 mg of nicorandil just after successful coronary reflow
(group A) and the other 10 patients who obtained successful coronary reflow
only (group B). Myocardial contrast echocardiography (MCE) was performed
beforeand15 minutes affercoronary reflow and 5minutesafterthe nicorandil
administration. MCE imageswere analyzed to determine peak contrast inten-
sity in the infarct and non-infarct areas, and their ratio (Pl ratio) was used to
assess microvascular integrity in the infarcl area. Regional wall motion in the
infarct area was serially assessed by two-dimensional echocardiography just
after coronary reflow and a month later (scores of O,normal, to 4, dyskinetic).
Thare was no difference in the wall motion score or the PI ratio juat after
coronary reflow between groups A (30 segments) and B (31 segments). ln-
tracoronary administration of nicorandil in group A improved the PI ratio from
0.27 + 0.25to 0.53 + 0.42 (p < 0.001), and provided greater improvement in
the wall motion score in a month compared to group B (2.8+ 0.7to 1.7 + 0.9
vs 2.7 & 0.5 to 2.4 + 0.8; p < 0.01). Thus we concluded that Intraooronaty
nicorandil administration restored blood flow within the infarct myocardium
and provided greater functional improvement in a month, suggestingthe
usefulnessof nicorandiladministrationas an adjunctivetreatmentfollowing
coronaryreflowinAMI patients,
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J.A. Rodriguez,1,Godoy,P.Castro,J.C. Quintana,E. Chavez, R. Corbelan.
Dept. of Cardiovascular Diseases, Catholic University of Chile, Santiago,
Chile
Leftventriculardilatationandprogreaaivesystolicdysfunctionfollowingacute
myocerdialinfarction(AMI) havebeen preventedby ACE inhibition.The rel-
ative importanceof aldosteronein this reaponse is uncertain. In a placebo
controlled, double blinded, randomized trial, we compared remipril (R) and
spironolactone (S), an aldostarone receptor antegoniet, in patients with im-
paired ejection fraction (EF) post AMI. Geometric left ventricular remodeling
was assessed baseline (B) and foliowing 6 months (m) of treatment. Patients
were randomly assigned to placebo (P, n = 18), R (2.5 mg b.i.d., n = 22)
or S (25 mg t.i.d., n = 15) on day 5 poet Ml. Groups were simiiar in age,
gender, AMI location, Killip class, incidence of thromboiysis (mean = 41%),
angioplasty (mean = 8%), surgical revascularization (mean = 5%) or addi-
tional medication: aspirin (mean = 90%), nitrates (mean = 31%), B-blockers
(mean = 28%), diuretics (mean = 18%) and digitalis (mean = 9%). Ejec-
tion fraction (EF), left ventricular end diastolic (EDVJand end systolic (ESV)
volumes were obtained by mitigated radionuclide angiography. Values are
expressed as mean + standard error.
EF(“A) EOV(ml) ESV(ml)
B 6m B 6m B 6m
P 39* 3 33* 3 127& S 166i 12 75& 6 109l 11
R 3sAZ 40* 2* 126& 7 143l 9 79& 6
s
88k 7*
33• 3 36& 3* 126+ 11 143* 10 S2+ 8 67& 6“
*p< 0,05,ANOVAofthedilferencas(treatedgroupsvs.placebo,)
We conclude that R and S provided comparable prevention of ventricular
dilatation and further decline in systolic dysfunction suggesting aldosterone
contributes to this geometrical remodeling and that antagonism of its receptor
may be equally efficacious to ACE inhibition.
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J. Kate,J. Tanouchi,T. Ito, M. Nishino,K. Iwai, H. Tanahashi,Y. Yamada,
T. Kamada.Oaaka Rosai Hospita/, Osaka, Japan
Previous experimental studies have reported that the inhibition of throm-
134A ABSTRACTS - Poster JACC February 1997
boxane A2 (TXA2) may prevent coronary thrombosis and thereby coronaty
obstruction. In this etudy we tested the hypothesis that sodium ozagrel (SO),
a TXA2 synthetase inhibitor, reduces intracoronary platelet deposition and
attenuates proliferative action of smooth muscle cell at sites of endothelial
injuty during primary coronary angioplasty (CA). Ninety-two patients (pts)
sewed with CA for firat acute myocardial infarction (AMI) were divided into
two groups; 44 pts without SO (Gl) and 48 pts with SO (G2). In Gl, only
routine hepatfn and isoaorbide dinitrate were administered during and early
after CA. In G2, in addition to the protocol, SO of 0.4 mg/Kg Intracoronary
bolus injection and of 1.2 mg/Kg intravenously (iv) infusion by 1 hour was
administered during CA, and additional SO of 1.6 mg/Kg iv by 1 hour was in-
fused at 12 hours after CA. Coronary restenosis was evaluated 5 days (lst),
4 weeks (2nd), 4 months (3rd) after CA in all pta. Resu/ts:Acute reocclusion
of infarct-related artery occurred in 2 (4%) of 46 pts with SO and 10 (23%) of
44 pta without SO (p < 0.01).
RD (mm) 6/A DN Post CA (“A) Ist (%) 2nd(“A) 3rd(OA)
G1 2.67+ 0.38 1.1+ 0.5 4.3+ 1.1 24i 9 39&27 48k 25 62&24
G2 2.59+0.34 1.0+0.3 4.2i 0.6 21i 13 27&21* 28+ 22” 47* 29*
RD: reference diameter, WA: balloonto artery ratio, DN: dilationnumbers,*P -= 0.05 vs
GI
While % etenosis was progreesively increased inGl, it was hindered in
G2 even with comparable CA reeults. Corrc/usiorrs:Thefindings indicate that
eodium ozagrel may prevent thrombotic reocdusion, which might attenuate
proliferative restenosis late affer CA. Thus, we conclude that sodium ozagrel
is a potential preventer of acute reocclusion and restenosis in pts with AMI
served with primary coronaty angioplasty.
1947-11I Bolu~magnesiuminfu~i~ni human~i~a~~~~iat*
withpredominantlyunfavorablechangeainplatelet
aggregationandcertainhemostaticfactors
V.L. Serebruany, W.R. Herzog, P.A.Gurbel. UrrionMemorial Hospital, and
The University of Maryland, Baltimore, MD, USA
The purpo$e of thia study was an attempt to extrapolate favorable obser-
vations of the effects of magnesium (Mg) on platelets and hemostasis from
the animal models to humans. We asseased the effect of bolua Mg infusion
on ex vivo platelet aggregation (PA) and certain hemostatic parameters in
healthy volunteers. One gram of Mg was diluted in 50 ml D5W and infused
over 15 minutes. The changes of PA, plasma antithrombin-111(AT-III),Protein
C (PC), total Protein S (PS), fibronectin (Fn), endothelin-1 (ET-l), as well as
the metebolites of thromboxane (Tx) and prostacyclin (PGI)were determined
prior to, and immediately after Mg infueion. SOrum Mg incrOasedfrom 2.1
+ 0.1 at baseline to 3.1 + 0.1 m@dL (p = 0.0002) post infusion and wee
associated with aignificent elevation in ADP- (+19.3Yo); rfstocetin- (+13.6%);
and collagen-induced (+14.27.) PA; increase in AT-III (+10.3Yo),and Tx
(+37.6%). In contract, PS (–20.7%), PC (-11.2%), and ET-1 (-26.3%) were
decreaeed. There were no significant differences in plasma Fn and PGI lev-
els. Acknowledging beneficial effect of Mg on vasoreactivity (diminished ET-1
level), increased platelet aggregability, acquired Protein Canal Protein Sdefi-
ciency, enhanced concentrations of Tx were found contrarily to expectations
based on the animal models. These findings indirectly support the 1S1S4re-
sults, denying clinical advantages of Mg therapy in patients with myocerdial
infarction. This etudy auggests that one must be cautious in drawing clinical
conclusions from the animal models, so as in speculations on the clinical
significance of experimental findings.
Gr-N than Gr-C. Compared to Gr-C, Gr-N showed the greater reduction in
LV volume and the better functional improvement. Conclusion: The intra-
venous N prevents the progression of microvascular damages in AMI and
this prevention seems to provide the better outcomes than repetfusion alone.
“/nNR ALVEDVI ALVESVI ARWM AWMSI
Nicorandil(n = 30) 13# –4,7 + 22.8# -8.4 + 14,6# 1,0 + 1.4# -1,0+ O.S#
Control(n= 30) 33 13.6 + 23.0 7.4 +21,S 0.2 +0.8 –0.5+0.6
#P<0.05 Vscontrol.A = IM vatue – ID value.
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-[ silentversus~ymptomati.~esiduallschaemi.
AtierThrombolysedMyocardialInfarctionin
PatientaRandomizedto MedicalTherapyor
Revascularization
T.T.Nielsen, U.H. Eriksen, P.Grande, J.K. Madsen, K. Saunam~ki,
P,Thayssen, E. Kassia, K. Rasmussen, S. Haunsa, T. Haghfelt, for the
DANAMI Study Group. Skejby University Hoapita/, Denmadr
The aim was to compare the long term benefit of invasive (PTCAand CABG)
versus consqwative treatment strategies in patients thrombolysed for their
first acute myocardial infarction who had symptomatic or silent post-infarction
ischemia.
Patients <70 years old with symptoms <12 hours and no previous AMI,
PTCA or CABG were recruited. To be included pte had to demonstrate.
post-infarction ischaemia: 1. Symptomatic angina pectoris presenting >36
hours after admission during hospital stay or during exercise test before
discharge, and/or 2. ST-deviation during exercise test> 0.1 mV.Two groupe
with post-infarction iachemiawere identified: Angina plua/minus documented
ischemia (n = 441, 44%) and silent ischemia (n = 567, 56%). Endpoints were
unstable angina (UAP), re-AMl, and death. Totally, 503 pts were randomized
to invasive strategy and 505 pts to conservative therapy,
Symptomatic RR
Coneerv. Invasive RR Conaew. Invasive RR
UAP 44.5”/0 27.6”A 0.62” 21.6% 13.2% 0.61”
re-AMl 13.3% 7.2”/a 0.54” 10.1% 5.7”/0 0.57”
Death 6.00/0 4.O”A 0.6S 3.s% 3.60/. 0.93
*p <0.05.
Cone/uaiorr:Compared to a mnservative strategy, “late” invasive treat-
ment almost halved the incidence of non-fatal reinfarction and admisaione
with unstable angina in thrombolysed AMI patients with symptomatic as well
as silent post-infarction ischemia, during a median of 2.4 years follow-up. No
reduction in death was found. Patients with symptomatic had more events
than patients with silent iachemia.
D94712 MicrovascularProtectionwithIntravenousNicorandilAugmentsMyocardialSalvagein
PatientawithAcuteMyocardialInfarction
T. Yoshiaki, L Hiroshi, 1.Kateuomi, N. Nagahiro, T. Shin, F. Kenahi. ,
Sakurabashi Watanabe Has-pital,Osaka, Japan
Experimental studiee documented that pharmacological protection of mi-
crovasculature against ischemic injury augments myooardial salvage.
In this study, we examined whether intravenous K+ channel opener (nico-
randil (N)) can prevent microvascular damage and whether this prevention
leads to the better functional improvement in 60 patients with reperfused
AMI. We divided the patients into 2 groups; N group (n = 30) and control (C)
group (n= 30). Intravenous N (4 mg bolus and 6 mg/h) was initiated >30 min
before reperfusion and wae Iaetedat least 24 hours, followed by oral admin-
istration (15 mg/day). We performed myocerdial contrast echocardiography
after reperfusion and determined the presence or absence of substantial no
reflow phenomenon (NR). We calculated the differences in LVvolumes (ml),
regional wall motion (RWM, SD/chord) and average wall motion score in
the infarct zone (WMSI, dye/akinesia = 3 to normal = O)between baseline
and follow-up (3 months) studies. F?eau/ts:Frequency of NR was lower in
1948-141 Tento14 YearFollow-Upof thelnteruniversity
CardiologyInstituteTrial:ImprovadLong-Term
SurvivalinAcuteMyocardialInfarctionPatients
TreatedWithEarlyThrombolyticTherapy
A.C.P. Maas, R.T.van Domburg, J. Vos, J.W. Deckers, F.Vermeer,
W.J. Remme, O. Kamp, V. Manger Cata, M.L. Simoons. Rotterdam,
Maastricht, Amsterdam and Leiden, The Netherlands
BackgrourrcVMethoda:In order to assess the long-term outcome of early
thrombolytic therapy in acute myocardial infarction (Ml), patients who partic-
ipated in the ICIN trial (n = 533) were followed-up for 10 to 14 years. Life
status was asseased and major cardiac events (re-Ml, PTCA, CABG) were
checked by hospital record review and enquiries to the general practitioner.
Resu/ts: At a median follow-up time of 11 years, survival was improved
significantly (p e 0.02) in patients (n = 269) treated with intracomnary strep-
tokinase (SK) as compared to conventionally treated (CT) patients (n = 264).
Suwival at 1, 5 and 10 yeare waa 91%, 61% and 69% in the SK group
and 64%, 71Y0and 59Y0in the CT group. Ten year freedom from death/re-
M1/CABGiPTCAwas 29% and 32% for SK and CT, respectively (p = ne).
Analysis of hospital survivor data revealed LVfunotion at discharge to be the
strongest independent predictor of long-term survival, followed by the extent
